Ovarian Ageing: What It Is, Symptoms and What It Means for Fertility

Ovarian ageing is a natural biological process – but it is one that affects far more than fertility alone.

The gradual decline in egg quantity and quality that begins before birth and accelerates through the mid-30s has wide-ranging implications for ovarian ageing symptoms; hormones, metabolism, bone health, cardiovascular risk, and long-term wellbeing.

Yet for many people, the first-time ovarian ageing becomes a real consideration is when they are already trying to conceive – by which point the window for proactive action may have narrowed.

Understanding what ovarian ageing is, how it progresses, what can accelerate it, and what your options are is not just relevant if you are planning a family. It is relevant to anyone who wants to understand their hormonal health, protect their long-term wellbeing, and make informed decisions at every stage of life.

 

Quick Facts

•       Females are born with a finite number of eggs – this supply cannot be replenished.

•       Ovarian reserve declines gradually throughout life, with the rate accelerating after the mid-30s.

•       Ovarian ageing affects hormones, metabolism, bone density, cardiovascular health, and mood – not just fertility.

•       Some people experience premature ovarian insufficiency (POI), where ovarian function declines significantly before the age of 40.

•       AMH (Anti-Müllerian hormone) is currently the most useful blood marker for assessing ovarian reserve.

•       A low AMH does not mean pregnancy is impossible – but it does mean the window for fertility planning may be shorter than expected.

•       Several factors beyond genetics can accelerate ovarian ageing, including endometriosis, certain surgeries, and lifestyle inputs.

 

 

What Is Ovarian Ageing?

 

Ovarian ageing refers to the gradual decline in both the number of eggs (ovarian reserve) and the quality of those eggs over time, alongside progressive changes in hormone production.

Unlike most other tissues in the body, the ovaries cannot generate new cells. Females are born with all the follicles they will ever have – typically around one to two million at birth, reducing to approximately 300,000–400,000 by puberty.

From that point, the decline continues steadily, with only a fraction of follicles ever reaching full maturity and ovulation. The rest undergo a process of natural cell death called atresia.

Alongside the reduction in egg number, egg quality also changes with age. Older eggs are more susceptible to chromosomal errors during division, which is why the likelihood of miscarriage and conditions such as Down’s syndrome increases as maternal age rises.

Menopause – the point at which periods stop permanently – marks the end stage of this process, typically occurring around age 51 in the UK. But the hormonal and biological changes associated with ovarian ageing begin years, or even decades, before menopause is reached.

 

 

Who Does Ovarian Ageing Affect?

 

Ovarian ageing is a universal process – it affects all people with ovaries. It is not a disease or a disorder. However, the timing and pace of this process vary considerably between individuals, and this variation has real implications for fertility planning and hormonal health.

Broadly, the timeline looks like this:

•       Throughout childhood and early adulthood, follicle numbers decline gradually and without noticeable effect.

•       From the early-to-mid 30s, the rate of follicle loss accelerates and egg quality begins to decline more noticeably.

•       In the late 30s and early 40s, fertility declines more steeply, and hormonal fluctuations may begin.

•       Perimenopause – the transition phase before menopause – typically begins in the mid-to-late 40s, though it can start earlier.

•       Menopause is reached when periods have been absent for 12 consecutive months, on average around age 51.

 

It is important to note that two people of the same age can have very different ovarian reserves.

A 35-year-old might have the ovarian reserve typically associated with a 28-year-old, or with a 42-year-old.

Age alone is a poor guide to ovarian function – which is why testing matters.

 

Signs and Symptoms of Ovarian Ageing

Ovarian ageing does not always produce obvious symptoms, particularly in its earlier stages.

For many people, declining ovarian reserve is entirely silent until fertility difficulties arise or blood testing reveals changes in hormone levels.

When symptoms do occur, they typically reflect the hormonal shifts associated with declining oestrogen, progesterone, and ovarian function.

These can include:

Changes in menstrual cycle length or regularity

Periods may become shorter, longer, heavier, lighter, or more irregular as ovarian hormone production fluctuates. Cycle shortening – where cycles that were previously 28–30 days become 24–26 days – is often one of the earliest signs of declining ovarian reserve.

 

Vasomotor symptoms (hot flushes and night sweats)

Sudden waves of heat, flushing, and sweating occur as declining oestrogen affects the hypothalamus – the brain’s thermostat. These can occur during the day or disrupt sleep as night sweats. In perimenopause, they are among the most commonly reported symptoms.

 

Sleep disturbances

Difficulty falling or staying asleep is common as hormones shift. This is partly driven by night sweats, and partly by the direct effect of oestrogen and progesterone on sleep architecture. Disrupted sleep compounds fatigue, mood changes, and cognitive symptoms.

 

Mood changes and cognitive symptoms

Increased irritability, low mood, anxiety, and difficulty concentrating (‘brain fog’) are frequently reported. Oestrogen plays an important role in serotonin and dopamine regulation, and its decline can directly influence mood and cognitive function – independently of lifestyle stress.

 

Vaginal dryness and genitourinary changes

Reduced oestrogen leads to thinning and drying of vaginal tissues (genitourinary syndrome of menopause), which can cause discomfort during sex, urinary urgency or frequency, and increased susceptibility to urinary tract infections.

 

Fatigue and reduced energy

Persistent fatigue that does not resolve with rest is a common complaint, driven by hormonal changes, disrupted sleep, and the effect of declining oestrogen on mitochondrial function and energy production at the cellular level.

 

Reduced libido

Changes in testosterone and oestrogen can reduce sexual desire. This is a physiological process, not simply a psychological one, and is a recognised and treatable aspect of hormonal decline.

 

 

What Happens in the Body During Ovarian Ageing?

The effects of ovarian ageing extend well beyond the reproductive system. The hormones produced by the ovaries – primarily oestrogen, progesterone, and testosterone – have receptors in virtually every tissue in the body. As their production declines, the downstream effects are widespread.

Bone density

Oestrogen is central to maintaining bone density. As levels fall, bone resorption begins to outpace bone formation, increasing the risk of osteopenia and osteoporosis. Bone loss accelerates most rapidly in the first few years after menopause, making early awareness important for long-term skeletal health.

 

Cardiovascular health

Oestrogen has protective effects on the cardiovascular system – it supports healthy blood vessel function, favourable lipid profiles, and insulin sensitivity. As ovarian function declines, cardiovascular risk increases. Women’s rates of heart disease, historically lower than men’s before menopause, begin to converge after it.

 

Metabolic function

Hormonal shifts affect glucose handling, fat distribution, and insulin sensitivity. Weight gain – particularly around the abdomen – becomes more common as oestrogen declines, even without changes in diet or activity. Insulin resistance and metabolic syndrome risk increase.

 

Cellular and oxidative changes

Lower oestrogen reduces cellular protection against oxidative stress, increasing susceptibility to DNA damage. Mitochondrial efficiency declines, contributing to fatigue and reduced resilience. Telomere shortening may accelerate, influencing cellular ageing and tissue repair capacity.

 

Inflammation

Oestrogen has anti-inflammatory properties. Its decline is associated with a rise in low-grade chronic inflammation – the same underlying mechanism implicated in cardiovascular disease, metabolic dysfunction, and a range of age-related conditions.

 

What Can Accelerate Ovarian Ageing?

While ovarian ageing is universal, its pace is not fixed. A number of factors can accelerate the decline in ovarian reserve beyond what would be expected for a given age.

Genetics

Family history is one of the strongest predictors of ovarian ageing trajectory. If a close female relative experienced early menopause or premature ovarian insufficiency, the risk of a similar pattern is elevated. Certain genetic variants – including FMR1 premutations (associated with Fragile X syndrome) and Turner syndrome – are specifically linked to early ovarian decline.

 

Endometriosis

Endometriosis, particularly endometriomas (ovarian cysts formed by endometriotic tissue), is associated with accelerated follicle loss. The inflammatory environment created by endometriosis may directly damage ovarian tissue, and surgical removal of endometriomas carries its own risk of reducing ovarian reserve – making careful surgical planning important.

 

Ovarian surgery

Any surgery involving the ovaries – including cyst removal, surgery for endometriosis, or ovarian drilling for PCOS – carries a risk of reducing ovarian reserve, depending on the amount of tissue affected. This risk should be discussed thoroughly with a surgeon before any ovarian procedure.

 

Chemotherapy and radiotherapy

Certain chemotherapy agents – particularly alkylating agents – are toxic to ovarian follicles and can significantly reduce ovarian reserve or trigger premature ovarian insufficiency. Pelvic radiotherapy can have similar effects. Oncofertility – fertility preservation before cancer treatment – is an increasingly important consideration for younger patients.

 

Autoimmune conditions

Autoimmune ovarian insufficiency occurs when the immune system produces antibodies against ovarian tissue. This is associated with other autoimmune conditions including thyroid disease, Addison’s disease, and type 1 diabetes. Autoimmune causes account for a significant proportion of premature ovarian insufficiency cases.

 

Smoking

Smoking is one of the most modifiable risk factors for accelerated ovarian ageing. Toxins in cigarette smoke are directly toxic to oocytes and granulosa cells. Smokers on average reach menopause one to two years earlier than non-smokers, and AMH levels are measurably lower in women who smoke.

 

Lifestyle and nutritional factors

Chronic psychological stress, poor sleep, nutritional deficiencies (particularly vitamin D, omega-3s, and antioxidant nutrients), and high levels of oxidative stress from diet or environmental exposure may all contribute to a less favourable ovarian ageing trajectory. While the evidence is less definitive than for the factors above, these are modifiable inputs worth addressing.

 

Premature Ovarian Insufficiency (POI)

Premature ovarian insufficiency (POI) – sometimes called premature menopause, though the two are not identical – is defined as a significant decline in ovarian function before the age of 40.

It affects approximately 1 in 100 women under 40 and 1 in 1,000 women under 30.

Unlike natural menopause, POI does not necessarily mean permanent loss of ovarian function. Around 5–10% of people with POI will have intermittent ovarian activity and may conceive spontaneously. However, fertility is significantly reduced and the long-term health implications – particularly for bone density and cardiovascular health – are more significant than for natural menopause at a typical age, because the period of oestrogen deficiency is longer.

Symptoms of POI may include:

•       Irregular or absent periods before the age of 40

•       Hot flushes and night sweats at a younger than expected age

•       Difficulty conceiving

•       Elevated FSH on blood testing (typically above 25 IU/L on two tests taken at least four weeks apart)

•       Low or undetectable AMH

•       Symptoms of oestrogen deficiency: fatigue, brain fog, low mood, vaginal dryness

 

POI is frequently under-diagnosed and under-treated. If you have irregular periods, are experiencing symptoms of hormonal change before the age of 40, or have a family history of early menopause, blood testing is an important first step.

 

AMH and Ovarian Reserve Testing

Anti-Müllerian hormone (AMH) is currently the most clinically useful marker for assessing ovarian reserve – the number of follicles remaining in the ovaries. It is produced by small, growing follicles and declines steadily with age as follicle numbers fall.

What AMH can tell you

AMH provides insight into follicle quantity – how many eggs are likely remaining. It is useful for fertility planning, predicting ovarian response to stimulation (for example in IVF), and monitoring the trajectory of ovarian ageing over time. Crucially, AMH often begins to fall years before menstrual irregularity appears, making it a valuable early indicator.

What AMH cannot tell you

AMH does not assess egg quality, which also declines with age and is equally important for fertility and pregnancy success. It does not reliably predict the ability to conceive naturally in any given cycle, and a low AMH does not mean pregnancy is impossible – it means the window may be narrower than average. AMH should always be interpreted alongside symptoms, cycle history, FSH, LH, and oestradiol for a complete picture.

How AMH changes over time

•       AMH is highest in early adulthood, typically peaking in the early-to-mid 20s.

•       Levels decline gradually through the late 20s and 30s.

•       The rate of decline often accelerates in the late 30s and early 40s.

•       AMH becomes very low or undetectable approaching menopause.

 

Other markers used alongside AMH

A comprehensive ovarian health assessment typically includes AMH alongside:

•       Follicle-stimulating hormone (FSH) – rises as ovarian reserve falls

•       Luteinising hormone (LH) – helps assess the LH:FSH ratio and ovulatory function

•       Oestradiol (E2) – provides context for FSH interpretation

•       Antral follicle count (AFC) on transvaginal ultrasound – a direct count of visible follicles

 

Viewed in isolation, AMH can be misleading. In context – alongside other markers, symptoms, and cycle history – it provides genuinely valuable insight for fertility planning and hormonal health assessment.

 

What Are Your Options If Ovarian Reserve Is Declining?

Understanding your ovarian reserve is not just about receiving a number – it is about having enough information to make decisions that matter. What those decisions look like will depend on your age, circumstances, and goals.

Egg freezing (oocyte cryopreservation)

Egg freezing allows eggs to be retrieved, frozen, and stored for potential future use. It does not guarantee a future pregnancy, but it can extend the window of fertility for people who are not yet ready to conceive. The success of egg freezing is strongly dependent on age at the time of freezing – eggs frozen in the late 20s or early 30s have significantly better outcomes than those frozen in the late 30s or beyond. Knowing your AMH early enough to make this decision in time is one of the most practical reasons to test.

 

IVF and assisted reproduction

For those trying to conceive, AMH and antral follicle count are used to guide IVF stimulation protocols. A lower ovarian reserve means fewer eggs are likely to be retrieved in each cycle, which influences treatment planning and expectations. IVF success rates are also strongly age-dependent, reflecting the dual decline in egg quantity and quality.

 

HRT and hormonal support

For those experiencing symptoms of perimenopause, early menopause, or POI, hormone replacement therapy (HRT) replaces declining oestrogen, progesterone, and sometimes testosterone. For women with POI in particular, HRT is recommended not only for symptom management but as a protective measure for bone density, cardiovascular health, and cognitive function – continuing until at least the average age of natural menopause.

 

Lifestyle optimisation

While lifestyle changes cannot reverse declining ovarian reserve, there is evidence that certain inputs support ovarian health and egg quality. These include: stopping smoking, optimising antioxidant nutrient intake (CoQ10, vitamin D, omega-3 fatty acids), maintaining a healthy weight, managing chronic stress, and prioritising sleep. These are most relevant for those who are actively trying to conceive or preparing for IVF.

 

Ovarian Ageing Is Not a Dead-End Diagnosis

Ovarian ageing is inevitable – but its impact is not uniform, and it is not something that simply happens to you without the possibility of response.

Knowing where you are on the ovarian ageing trajectory creates options: options to plan, to act, to protect your longer-term health, and to make decisions from a position of information rather than uncertainty.

The earlier that awareness comes, the wider those options tend to be.

At My Atlas, we assess ovarian reserve as part of a broader picture of female hormonal health – not in isolation, but alongside the metabolic, adrenal, thyroid, and nutritional markers that give context to what the numbers actually mean for you.

Because ovarian health does not exist in a vacuum – and neither do you.

Frequently Asked Questions

What is ovarian ageing?

Ovarian ageing refers to the gradual decline in the number and quality of eggs (ovarian reserve), along with progressive changes in hormone production, that occurs naturally over a woman’s lifetime. The process begins before birth and accelerates from the mid-30s, eventually leading to menopause.

 

At what age does ovarian ageing begin?

Technically, ovarian ageing begins before birth – the number of follicles is at its peak in the foetus and declines from that point. The process accelerates noticeably from the mid-30s, and hormonal changes associated with perimenopause often begin in the mid-to-late 40s, though the timing varies significantly between individuals.

 

What is a normal AMH level?

AMH levels vary significantly with age and between individuals. Broadly, levels above 1.0 ng/mL are generally considered within a normal range for reproductive-age women, while levels below 0.5–1.0 ng/mL may indicate reduced ovarian reserve.

However, ‘normal’ is always relative to age, and an AMH result should be interpreted in context – alongside symptoms, other hormone markers, and cycle history – rather than in isolation.

 

Can you get pregnant with a low AMH?

Yes – a low AMH does not mean pregnancy is impossible. AMH reflects the quantity of remaining follicles, not egg quality, and people conceive naturally with low AMH. What it does indicate is that the window of fertility may be shorter than average, and that ovarian reserve is declining.

If you have a low AMH and are considering pregnancy, speaking with a fertility specialist sooner rather than later is advisable.

 

What is premature ovarian insufficiency (POI)?

POI is defined as significant decline in ovarian function before the age of 40. It affects around 1 in 100 women under 40 and can be caused by genetic factors, autoimmune conditions, chemotherapy, or surgery – or may have no identifiable cause.

It differs from natural menopause in that ovarian function may be intermittent rather than fully ceased, and the long-term health implications are more significant due to the longer duration of oestrogen deficiency.

 

Does ovarian ageing affect more than fertility?

Yes – significantly so. The hormones produced by the ovaries affect bone density, cardiovascular health, metabolic function, mood, cognitive function, sleep, and inflammation.

Ovarian ageing is as much a whole-body process as a reproductive one, and understanding and managing it has long-term health implications well beyond fertility.

 

How is ovarian reserve tested?

The most commonly used tests are AMH (anti-Müllerian hormone) via a blood test, FSH and oestradiol (typically measured on day 2–5 of the cycle), and antral follicle count (AFC) via transvaginal ultrasound.

AMH has the advantage of being measurable at any point in the cycle. A comprehensive assessment uses several of these markers together rather than relying on any single result.

 

 

References

This article was written by Holly Devine and reviewed for clinical accuracy. It is intended for informational purposes only and does not constitute medical advice. If you have concerns about your ovarian health or fertility, please consult a qualified healthcare professional.

 

Ovarian reserve and AMH

•       Anderson RA, Nelson SM, Wallace WH. Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas. 2012;71(1):28–33.

•       Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertility and Sterility. 2009;91(3):705–714.

•       Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Müllerian hormone in women. Human Reproduction Update. 2014;20(3):370–385.

 

Premature ovarian insufficiency

•       European Society of Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926–937.

•       Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction. 2016;31(5):926–937.

•       Royal College of Obstetricians and Gynaecologists. Premature Ovarian Insufficiency. Scientific Impact Paper No. 77. rcog.org.uk (2023). Available at: https://www.rcog.org.uk

 

Ovarian ageing and systemic health

•       Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cardiovascular disease: a population-based study. Maturitas. 2014;63(1):79–85.

•       Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. Journal of Clinical Endocrinology & Metabolism. 2008;93(3):861–868.

•       Carr MC. The emergence of the metabolic syndrome with menopause. Journal of Clinical Endocrinology & Metabolism. 2003;88(6):2404–2411.

 

Factors affecting ovarian reserve

•       Somigliana E, Berlanda N, Benaglia L, et al. Surgical excision of endometriomas versus ovarian cystectomy for endometrioma-associated infertility: a systematic review. Fertility and Sterility. 2012;98(6):1531–1537.

•       Plante BJ, Cooper GS, Baird DD, Steiner AZ. The impact of smoking on antimullerian hormone levels in women aged 38 to 50 years. Menopause. 2010;17(3):571–576.

•       Grynnerup AG, Lindhard A, Sørensen S. The role of anti-Müllerian hormone in female fertility and infertility – an overview. Acta Obstetricia et Gynecologica Scandinavica. 2012;91(11):1252–1260.